Your browser doesn't support javascript.
loading
Icotinib derivatives as tyrosine kinase inhibitors with anti-esophageal squamous carcinoma activity.
Chen, Xiaojie; Mao, Long-Fei; Tian, Siqi; Tian, Xueli; Meng, Xueqiong; Wang, Mu-Kuo; Xu, Weifeng; Li, Yue-Ming; Liu, Kangdong; Dong, Zigang.
Affiliation
  • Chen X; School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, China.
  • Mao LF; The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
  • Tian S; China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.
  • Tian X; School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, China.
  • Meng X; State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, Tianjin, China.
  • Wang MK; School of Chemistry and Chemical Engineering, Henan Normal University, Henan Engineering Research Center of Chiral Hydroxyl Pharmaceutical, Xinxiang, China.
  • Xu W; School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, China.
  • Li YM; China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.
  • Liu K; School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, China.
  • Dong Z; School of Chemistry and Chemical Engineering, Henan Normal University, Henan Engineering Research Center of Chiral Hydroxyl Pharmaceutical, Xinxiang, China.
Front Pharmacol ; 13: 1028692, 2022.
Article in En | MEDLINE | ID: mdl-36467103
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Pharmacol Year: 2022 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Pharmacol Year: 2022 Document type: Article